RxDoctor Payments Data

Ralph Brown, MD

Physical Medicine & Rehabilitation · Christiansburg, VANPI 1215916556

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.5% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 33.9% of the total. Reporting peaked in 2019 at $673 and has fallen 75.1% since, to $168 in 2024.

$2,382in general payments, 2019–2025

Across 141 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$807
  • Teva Pharmaceuticals USA, Inc.$326
  • Smith+Nephew$167
  • Lilly USA, LLC$135
  • Biodelivery Sciences International, Inc.$126
  • Amgen$122
  • plus $699 from 20 others

What the payments were for

  • Food & beverage$2,34698%
  • Education$362%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,382 in reported general payments places this provider in the 85th percentile of 231 physical medicine & rehabilitation providers in Virginia.

See all physical medicine & rehabilitation providers in Virginia

Medicare billing

Part B allowed, 2024
$33,152
Medicare patients
147
Services billed
443

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuedextaDextromethorphan Hbr/Quinidine30$39,851
UbrelvyUbrogepant12$19,945
MyrbetriqMirabegron25$11,395
Baclofen235$7,478
Gabapentin291$6,626
TrintellixVortioxetine Hydrobromide13$6,407
Methenamine Hippurate57$5,511
Pregabalin186$5,291
Tizanidine Hcl116$4,610
Nucynta ErTapentadol Hcl11$3,591
Topiramate ErTopiramate13$2,919
Bromocriptine Mesylate11$2,111
Oxybutynin Chloride ErOxybutynin Chloride23$1,841
Mexiletine Hcl18$1,491
Calcitonin-SalmonCalcitonin,salmon,synthetic12$1,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Avanir Pharmaceuticals, Inc.Nuedexta$107$39,85130 claims
AbbVieUbrelvy$807$19,94512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 231 physical medicine & rehabilitation providers in Virginia.

Other physical medicine & rehabilitation in Christiansburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →